Archives

Biggest changes for 10 years: earlier ART, treatment as prevention, efavirenz dropped… and new challenges for the NHS… New online guide and A5 booklet.

IAS 2015 – a time of global change for HIV care: over a dozen reports on why this conference news is so exciting…

START results in full, WHO recommends ART for all, HIV cure research, webcasts access, treatment as prevention in HPTN 052, HIV remission in a teenager, dispersible dolutegravir for kids, new ARVs and more…

Activist review of latest research into HIV, HCV and TB: drugs for adults and children, dose optimisation, diagnostics, prevention, cure and vaccines…

Remembering Professor Martin Fisher, breaking news on the START study, reports from BHIVA, CROI and HIV & Women conferences and much more…

On Thursday 2 June, health activists led by ACT UP London held a protest in Soho to demonstrate access to PrEP for people at high risk of HIV infection. The demonstration was loud and active – forming a line from …

This blog is mainly a link page to three recent articles about the START study. A technical report in HIV Treatment Bulletin mainly for health professionals. i-base.info/htb/28261 A non-technical report to explain the implications of the results for HIV positive …

What is the START study? The START study is a large international HIV study. It looks at the risks and benefit of early HIV treatment. “Early” is defined as having a CD4 count above 500. Results are compared to a …

At least 18 months earlier than expected, these results will change treatment guidelines globally…

elite controller (EC) – if your viral load stays undetectable for more than five years without ART you are an elite controller. Elite controllers also have a very good CD4 count (always above 500 cells/mm3) that stays at a similar level over …

long-term non-progressor (LTNP) – An HIV positive person whose CD4 count stays above 500 copies/mm3 with very low viral load for more than five years, without using ART. Some LTNPs have kept their CD4 count above 500 for more than …

This talk was for the British HIV Association spring conference. It was a small study lead by advocates at i-Base and was selected by the conference for an oral presentation (Abstract O_4). The study calculated readability scores from nine ongoing …

Guia qué debo saber la coinfección por hepatitis C y VIH? – PDF (5.9 Mb) i-Base/TAG Guide to HIV/HCV coinfection. Translated and adaption by HIV treatment activist organisation Grupo de Trabajo sobre Tratamientos del VIH (gTt) in Barcelona. http://www.gtt-vih.org

News, comment and reviews of more than 50 studies in 16 articles from CROI 2015 and 4 from the International Drug Resistance Workshop…

All about PrEP – 6 studies plus ART prevention, 3-drug ART for PMTCT, HIV drug resistance, new drugs: TAF and maturation inhibitors, why TEMPRANO does not support early ART, weekends-off ART for some young people…

 Rastreio da infeção pelo VIH e riscos de transmissão sexual 2015 February 2015 (Portuguese) PDF (2.8 MB) Translated and produced by the HIV activist organisation Grupo Português de Activistas sobre Tratamentos de VIH/SIDA (GAT) in Lisbon. www.gatportugal.org Other translations of i-Base resources.

From the i-Base guide to changing treatment (2015) Figure 4: How one mutation can stop some drugs working Some drugs stop working after only one mutation. These include NNRTIs (nevirapine, efavirenz, rilpivirine and etravirine), integrase inhibitors (raltegravir) and some nukes (3TC  …

From the i-Base guide to changing treatment. Figure 1. Viral load blips A single blip above 50 is common. It doesn’t mean you need to change treatment. A blip is usually undetectable again on the confirmatory test. Figure 2. Viral …

From the i-Base guide to changing treatment (2015) Figure 3. From rebound to symptoms Viral load rebounds. If you stay on the same meds, viral load will continue to rise. Your CD4 count will go down over time. As your CD4 …

Reports from hepatitis and TB meetings, dolutegravir in England, new London guidelines, India rejects patent for Gilead’s sofosbuvir, plus more…